No matches

5 search results for: Airway Hyperresponsiveness

Pulmonology

Airway Hyperresponsiveness In Asthma Is Mainly Driven By Components Of Type 2 Inflammation

5 min

interactivity

Examine underlying type 2 inflammation as a driver of airway hyperresponsiveness in patients with asthma.

Pulmonology

Airway Hyperresponsiveness In Asthma Is Mainly Driven By Components Of Type 2 Inflammation

5 min

interactivity

Examine underlying type 2 inflammation as a driver of airway hyperresponsiveness in patients with asthma.

ADVENT On Air | Diving Deep: Exploring the Impact of <b>Airway</b> Remodeling in Severe Asthma

Pulmonology

ADVENT On Air | Diving Deep: Exploring the Impact of Airway Remodeling in Severe Asthma

20 min

Podcast

Join Dr. Mario Castro and Prof. Vibeke Backer as they discuss airway remodeling and airway hyperresponsiveness and their impact in the lives of patients with severe asthma.

ERS 2024 | Can Biologics Affect <b>Airway</b> Remodeling?

Pulmonology

ERS 2024 | Can Biologics Affect Airway Remodeling?

20 min

expert video

Dr Mario Castro presents the latest clinical data on biologics showcasing their effect on airway remodeling parameters and airway hyperresponsiveness in patients with severe asthma.

Screen depicting a mucus plug in the airways

Pulmonology

A view into the Airway: The Pathophysiology and Clinical Relevance of Mucus Plugs in Asthma

4 min

videoanimation

Explore the role of type 2 inflammation in the production of mucus plugs in asthma and the effects these plugs can have on patients.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: ArgentinaChange country/region